Brain+ CEO: “CST is becoming the standard in dementia care”
Brain+ is a health tech company focused on treatment and management of dementia. Centred around Cognitive Stimulation Therapy, the company's approach has the potential...
BioStock Investor Pitch: Brain+
Brain+ is a health tech company focused on treatment and management of dementia. Centred around Cognitive Stimulation Therapy, the company's approach has the potential...
Aqilion aims for best-in-class with new programme
Aqilion is in the business of discovering and developing new drug targets that could reduce the burden of chronic inflammatory illnesses. The company has...
Alligator Bioscience on the importance of prolonging life
What does time mean to a person who's cancer might not be cured? Prolonged life can bring hope for alternative treatments, or simply allow...
BioStock Investor Pitch: Alligator Bioscience
How is Alligator Bioscience preparing to move forward after FDA approval? CEO Søren Bregenholt presents the company, which develops tumour-directed antibodies, and gives us...
Asgard’s CEO on the EUR 30 million Series A financing
Asgard Therapeutics is a biotech based in Lund developing an immune "Trojan horse" to defeat cancer. The company recently announced a EUR 30 million...
BioStock Investor Pitch: Biosergen
In the BioStock Studio, Swedish Biosergen talks about the company’s vision, market plan and strategy to take its product through the first patient study...
Chordate’s CEO presented at Swiss Nordic Bio
On March 7, Swiss Nordic Bio convened for its annual partnering and investor conference, facilitating connections between Nordic and Swiss life science companies, investors,...
Biosergen attacks invisible threat of fungal infections
How big is the threat of fungal infections and the strains that develop drug resistance? Swedish biotech company Biosergen develops antimyotic drugs that they...
Alligator’s CEO comments on restructuring plan
Alligator Bioscience is coming off a high after reaching the primary endpoint in the OPTIMIZE-1 phase II trial with lead candidate mitazalimab. However, together...